Cooley advised Orphai Therapeutics, a clinical-stage biotechnology company, on its sale to Quince Therapeutics, a biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. The acquisition brings Orphai’s lead program LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor), to treat rare pulmonary diseases, into Quince’s pipeline.